|Day Low/High||228.68 / 232.90|
|52 Wk Low/High||104.28 / 240.76|
Painkiller manufacturers might see their profits hurt by medical cannabis in the near future.
The only other option is 'to fearfully wait' for the legal-weed industry to expand.
It is entirely possible that a business relationship with Canopy Growth will help Constellation Brands, but the charts currently suggest further risk for the beverage company.
Covered calls may be the best bet -- or wait for a dip.
This options trade combines some upside with a chance to buy TLRY at a decent price.
The cannabis company has gained DEA approval to import a cannabinoid drug into the U.S.
Expect more companies to join Coca-Cola, Molson Coors and Constellation Brands in checking out the market.
A tie-up between the two could mark the first major U.S. firm to establish a line of CBD drinks.
The latest reports about Coke looking into cannabis confirms a broader industry trend.
You don't want your money to go up in smoke.
A brewer facing challenges, a banking giant and a retail behemoth are ripe for downside plays.
Not every cannabis stock was strong on Wednesday. One significant Canadian name sure was though.
Moody's and Zacks aren't seeing the potential for CBD drinks or even THC drinks.
Hexo is pursuing joint ventures in cosmetics, health care, candy, edibles, and vape companies.
Analysts and advisors stand by Nike as NFL.
Tilray reported a 95% jump in second-quarter revenue to $9.7 million, ahead of the Wall Street estimate of $9 million, in its first earnings release since it went public on July 19.
Seasonality hasn't mattered in a number or years so why should light volume new highs be an issue?
Two companies, PepsiCo and Constellation Brands, are disrupting their own businesses and getting no credit whatsoever for doing so.
Even bullish analysts are cautious on Constellation's big cannabis bet.
Odds are good that you'll make at least 8% in 37 days using this put play.
Odds are good that you'll make at least 8% in 37 days using this play.
Constellation Brand's bigger stake in Canopy has analysts mulling the prospects of a takeover.
With the price of CGC up around 8% this morning a fresh look at the charts is in order.
CGC and STZ should both remain 'go to' plays on the marijuana industry.
Beer companies are going to greater lengths to grow.